ASCO 2024: Immunotherapy for the Treatment of Small Cell Lung Cancer - Episode 11
Reviewing Ideate-Lung02: Durable Responses in Advanced SCLC
Medical experts review the Ideate-Lung02 phase 3 clinical trial, exploring the potential for ifinatamab to elicit durable responses in patients with advanced small cell lung cancer (SCLC), and discussing the implications of these findings for the future treatment landscape of SCLC.
Video content above is prompted by the following questions:
- B. Ideate-Lung02: Phase 3 Clinical Trial of Ifinatamab Deruxtecan vs TPC in Relapsed ES-SCL [TPS8126]
- Please share your perceptions of the potential for durable response to ifinatamab, a B7-H3-directed ADC in patients with previously treated, relapsed SCLC.
- How encouraging is an ORR of 52.4%, a 5.9-month median DoR, and a 12.2-month
- OS after a median 2 prior lines of therapy as reported in the Phase I/II trial?
- Currently, can you assay B7-H3 to determine individual expression levels?
- How does a treatment schedule of 12 mg/kg IV Q3W compare with that of:
- amrubicin [(Calsed) aminoanthracycline]: 45mg/m2 IV Infusion QD x 3 days Q3W [Japan]
- topotecan [(Hycamtin) topoisomerase inhibitor]: 1.5 mg/m2 IV infusion QD, Days 1-5 Q3W
- lurbinectedin [(Zepzelca) alkylating agent]: 3.2 mg/m2IV infusion Q3W
- What is the potential for immunogenicity with this ADC, and which treatment-related adverse events would most concern you?
Related Content:
